Form 4: Strata Critical Medical Grants CAO Cohen 64,191 RSUs

Strata Critical Medical, Inc. has granted its Chief Accounting Officer, Amir Cohen, 64,191 Restricted Stock Units with a vesting schedule extending to March 2030.

Summary

• Amir Cohen, Chief Accounting Officer of Strata Critical Medical, Inc. (SRTA), was granted 64,191 shares of Class A common stock.
• The transaction occurred on February 24, 2026, with a price of $0 per share, indicating a grant rather than a purchase.
• These shares represent Restricted Stock Units (RSUs) that will vest over time.
• Following this grant, Mr. Cohen beneficially owns 181,817 shares directly.
• The vesting schedule for the RSUs is 6.25% every three months after March 8, 2026, with all remaining unvested RSUs vesting on March 8, 2030, contingent on Mr. Cohen's continued service to the Issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices aimed at retaining key talent and aligning management incentives with long-term company performance.

Positives

• The grant of Restricted Stock Units (RSUs) to the Chief Accounting Officer aligns management's interests with long-term shareholder value.
• The multi-year vesting schedule encourages retention of a key executive.

Risks

• The vesting of RSUs is contingent on the reporting person's continued service, meaning the company risks losing the executive if service is not continued, potentially impacting financial reporting stability.
• Future share price performance could impact the value of the compensation, potentially affecting executive motivation if the stock underperforms.

Future Outlook

The vesting schedule for the granted RSUs extends to March 8, 2030, indicating a long-term retention strategy for the Chief Accounting Officer, contingent on continued service to the Issuer.

Industry Context

StockSavvy.ai notes that granting Restricted Stock Units (RSUs) is a common practice in the technology and medical device sectors for executive compensation, aiming to align management incentives with long-term shareholder value and ensure executive retention. This practice is standard across publicly traded companies to attract and retain top talent.

Comparison to Industry Standards

• The RSU grant to a Chief Accounting Officer is a standard executive compensation tool, comparable to practices at companies like Medtronic (MDT) or Stryker (SYK), which frequently use equity awards to incentivize key personnel.
• The multi-year vesting schedule, extending to four years, is typical for executive equity grants, similar to programs seen at major healthcare technology firms, ensuring long-term commitment.

Stakeholder Impact

• Shareholders: Potential minor dilution from future share issuance upon vesting, but also potential benefit from improved executive retention and performance alignment.
• Employees: May signal stability in executive leadership.
• Management: Amir Cohen's compensation is now more directly tied to the company's long-term stock performance.

Next Steps

• Continued service of Amir Cohen to the Issuer to ensure vesting of RSUs.
• Future quarterly vesting events for the granted RSUs commencing after March 8, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (RSU grant) and does not contain information that would fundamentally alter the investment thesis for Strata Critical Medical, Inc. It reinforces executive retention but offers no new operational or financial data to warrant a change in investment stance.

Keywords

Strata Critical Medical, SRTA, Amir Cohen, Chief Accounting Officer, Restricted Stock Units, RSU grant, executive compensation, insider transaction, Form 4, beneficial ownership